PureTech's LYT-300 hits Phase IIa primary endpoint

Boston, USA-based PureTech Health (Nasdaq: PRTC, LSE: PRTC) saw its London-listed share edge up 1.6% to 176.00 pence, after it announced top-line results from its Phase IIa, randomized, placebo-controlled, proof-of-concept trial of LYT-300 (oral allopregnanolone) in anxiety.

The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.

PureTech noted that oral administration of LYT-300 achieved the trial’s primary endpoint of a statistically-significant reduction versus placebo in the increase from baseline to peak levels of the stress hormone salivary cortisol (p=0.0001). The LYT-300 treatment effect size versus placebo was 0.72, as measured by Cohen’s d, which is one of the most common ways to measure effect size.